PBB-8-IN is a long acting FVIII, which PBB intends to trial in HA patients with inhibitors. About 25-30% of severe HA patients develop inhibitors to FVIII replacement therapy, rendering such therapy ineffective. These patients either take on-demand bypass therapies losing the benefits of prophylactic treatment, or undergo costly and unpleasant Immune Tolerance Induction therapy.

PBB intends to begin a Ph II clinical trial in 2018.